{"id":"W4408762849","doi":"10.1093/neuonc/noaf079","title":"A multi-institutional phase 1 clinical trial exploring upfront multimodal standard of care and combined immunotherapies for newly diagnosed glioblastoma","year":2025,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institutes of Health; ECOG-ACRIN Cancer Research Group; Mallinckrodt Pharmaceuticals; Society for Immunotherapy of Cancer; Regeneron Pharmaceuticals; Genentech; University of Pittsburgh; American College of Radiology Imaging Network; EMD Serono; International Association for the Study of Lung Cancer; Gilead Sciences; National Cancer Institute; Brigham and Women's Hospital; Daiichi Sankyo Europe; Sanofi; G1 Therapeutics; Celgene; Bristol-Myers Squibb; AstraZeneca; Bill and Melinda Gates Foundation; Amgen; University of Texas MD Anderson Cancer Center; Pfizer","keywords":"Medicine; Nivolumab; Regimen; Immunotherapy; Immune system; Oncology; Clinical trial; Internal medicine; Temozolomide; Adjuvant; Immunology; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002060079,0.001485606,0.001280109,0.0007015768,0.0004520251,0.0008225823,0.001085775,0.001138554,0.002887977],"category_scores_gemma":[0.0008941551,0.0004671937,0.0008158743,0.0005074343,0.0008040963,0.0009078619,0.0005592659,0.002727704,0.0005074373],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009078701,"about_ca_system_score_gemma":0.001481784,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006997305,"about_ca_topic_score_gemma":0.002517204,"domain_scores_codex":[0.9992945,0.0003525237,0.0000363338,0.0001251789,0.00006868639,0.0001226411],"domain_scores_gemma":[0.9990963,0.0001052997,0.0002145665,0.00009974718,0.00006788234,0.0004161563],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.734637,0.1067586,0.01331382,0.0005766198,0.00115222,0.0001665541,0.0002070121,0.002435062,0.04313402,0.0001579223,0.00182795,0.09563325],"study_design_scores_gemma":[0.3218737,0.653755,0.01671142,0.00003300445,0.0003616168,0.0002170364,0.00004910918,0.001081575,0.004680953,0.0001282659,0.00107862,0.00002961212],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966709,0.0006815699,0.0002687331,0.000168796,0.00004176177,0.001402082,0.0002968856,0.0000310456,0.000438343],"genre_scores_gemma":[0.991381,0.0008294873,0.002248987,0.0004838447,0.0001423504,0.002695018,0.001279593,0.00001469994,0.0009249674],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002887977,"threshold_uncertainty_score":0.01089489,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06658925152181847,"score_gpt":0.3950314875406087,"score_spread":0.3284422360187903,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}